Stock NEWBRY NEWBURY PHARMACEUTICALS AB
Add to a list
To use this feature you must be a member
Log inSign up

Newbury Pharmaceuticals AB Share Price

Equities

NEWBRY

SE0015244884

Drug Retailers

Market Closed - Nasdaq Stockholm
Other stock markets
 14:12:34 23/05/2024 BST 		5-day change 1st Jan Change
3.15 SEK -0.32% Intraday chart for Newbury Pharmaceuticals AB +0.96% +2.61%
04-10 Newbury Pharmaceuticals AB Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024 CI
02-22 Newbury Pharmaceuticals Secures SEK9 Million Sales Order MT

Financials

Sales 2024 * 38.4M 3.58M 282M Sales 2025 * 72.4M 6.75M 531M Capitalization 76.41M 7.12M 561M
Net income 2024 * -10M -932K -73.4M Net income 2025 * 3M 280K 22.02M EV / Sales 2024 * 2.69 x
Net Debt 2024 * 27M 2.52M 198M Net Debt 2025 * 39M 3.64M 286M EV / Sales 2025 * 1.59 x
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees 5
Yield 2024 *
-
Yield 2025 *
-
Free-Float 46.13%
More Fundamentals * Assessed data

Chart Newbury Pharmaceuticals AB

Dynamic Chart

Latest news about Newbury Pharmaceuticals AB

Newbury Pharmaceuticals AB Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024 CI
Newbury Pharmaceuticals Secures SEK9 Million Sales Order MT
Newbury Pharmaceuticals Receives International Sales Order Valued At 8.8 Million CI
Newbury Pharmaceuticals AB Reports Earnings Results for the First Quarter Ended November 30, 2023 CI
Newbury Pharmaceuticals AB Reports Earnings Results for the Full Year Ended August 31, 2023 CI
Newbury Pharmaceuticals AB Reports Earnings Results for the Fourth Quarter Ended August 31, 2023 CI
Newbury, Amarox Sign Distribution Deal for Sweden, Denmark MT
Newbury Signs Contract with Amarox Limited to Represent and Distribute Their Products in Sweden and Denmark CI
Newbury Pharmaceuticals Strengthens its Portfolio with Levodopa/Benserazide CI
Newbury Secures Access to Hospital Product Portfolio in New Partnership MT
Newbury Pharmaceuticals AB Gains Access to the Nordic Hospital Market with A New Strategic Partnership for Prescription Medicine CI
Newbury Pharmaceuticals Gets OK to Sell Peptide Product in Sweden MT
Newbury Pharmaceuticals Announces the Marketing Authorization of Desmopressin Newbury 60, 120 & 240 Mg Sublingual Tablets in Sweden CI
Newbury Pharmaceuticals AB Provides Earnings Guidance for the Year 2028 CI
Newbury Pharmaceuticals AB Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2023 CI
More news

Press releases Newbury Pharmaceuticals AB

Newbury Pharmaceuticals Q2 - A bump in the road AQ
Newbury Pharmaceuticals interim report September 2023 – February 2024 AQ
Newbury Pharmaceuticals carries out a directed share issue of approximately SEK 19 million AQ
Newbury Pharmaceuticals receives international sales order valued at 8.8 million SEK AQ
Nintedanib Newbury approved by the Swedish Health Authorities AQ
More press releases

Quotes and Performance

1 day-0.32%
1 week+0.96%
Current month-7.62%
1 month-9.74%
3 months-28.25%
6 months-12.26%
Current year+2.61%
More quotes

Highs and lows

1 week
2.93
Extreme 2.93
3.18
1 month
2.75
Extreme 2.75
3.98
Current year
2.75
Extreme 2.75
6.24
1 year
2.50
Extreme 2.5
6.24
3 years
2.50
Extreme 2.5
13.70
5 years
2.50
Extreme 2.5
13.70
10 years
2.50
Extreme 2.5
13.70
More quotes

Managers and Directors - Newbury Pharmaceuticals AB

Managers TitleAgeSince
Lars Minor CEO
 Chief Executive Officer 53 31/12/20
Christoffer Tell DFI
 Director of Finance/CFO 37 31/12/20
Andrea Karnitschky BRD
 Director/Board Member - 31/07/22
Members of the board TitleAgeSince
Karl Alexius Tiger Karlsson FOU
 Founder 50 31/12/19
Hakan Andreas Hedskog BRD
 Director/Board Member 50 31/12/19
Johan Strömqvist BRD
 Director/Board Member 48 31/12/19
More insiders

Quotes

Date Price Change Volume
23/05/24 3.15 -0.32% 2,262
22/05/24 3.16 +7.85% 40,051
21/05/24 2.93 -2.98% 13,467
20/05/24 3.02 -2.58% 23,260
17/05/24 3.1 -0.64% 421

Delayed Quote Nasdaq Stockholm, May 23, 2024 at 02:12 pm

More quotes

Company Profile

Newbury Pharmaceuticals AB is a Sweden-based pharmaceutical company for specialty prescription drugs. The Company’s existing portfolio is focused on the Scandinavian market and consists of pharmaceuticals from several therapeutic areas with oncology, rare diseases and neurology.
Sector
Drug Retailers
More about the company

Income Statement Evolution

More financial data

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Retail - Drugs without Grocery

1st Jan change Capi.
NEWBURY PHARMACEUTICALS AB Stock Newbury Pharmaceuticals AB
+2.61% 7.14M
AIN HOLDINGS INC. Stock Ain Holdings Inc.
+30.24% 1.31B
QOL HOLDINGS CO., LTD. Stock Qol Holdings Co., Ltd.
-11.59% 352M
NIHON CHOUZAI CO.,LTD. Stock NIHON CHOUZAI Co.,Ltd.
+3.72% 275M
SALUS, LJUBLJANA, D. D. Stock SALUS, Ljubljana, d. d.
+12.22% 231M
GREEN CROSS HEALTH LIMITED Stock Green Cross Health Limited
-9.17% 87.58M
PETMED EXPRESS, INC. Stock PetMed Express, Inc.
-46.56% 84.03M
MEDICAL IKKOU GROUP CO.,LTD. Stock Medical Ikkou Group Co.,Ltd.
+21.23% 60.04M
Retail - Drugs without Grocery
  1. Stock Market
  2. Equities
  3. NEWBRY Stock